# IsKia (NCT04483739)

> Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04483739
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: European Myeloma Network B.V.
- Conditions: Multiple Myeloma
- Interventions: Carfilzomib Lenalidomide Dexamethasone; Isatuximab Carfilzomib Lenalidomide Dexamethasone
- Enrollment: 302
- Primary outcome: Rate of MRD negativity after ASCT consolidation treatment by NGS

## Commentary we found

- X threads: 46
- YouTube: 24
- Podcasts: 15

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=iskia-nct04483739

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04483739", "email": "<work email>"}; the inbox owner confirms by the emailed link.